Astrazeneca sees a profit rise despite the Chinese allegations of imports




The profit after the tax increased to $ 7 billion last year, which is USD $ 6 billion in 2023, the company said, noting a sudden increase in cancer drug sales. Read more



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *